The HRAS1 minisatellite locus and risk of ovarian cancer.

Approximately 10% of ovarian cancers are due to mutations in highly penetrant inherited cancer susceptibility genes. The highly polymorphic HRAS1 minisatellite locus, located just downstream from the proto-oncogene H-ras-1 on chromosome 11p, consists of four common progenitor alleles and several dozen rare alleles, which apparently derive from mutations of the progenitors. Mutant alleles of this locus represent a major risk factor for cancers of the breast, colorectum, and bladder, and it was found that BRCAI mutation carriers with at least one rare HRAS1 allele have a greater risk of ovarian cancer than BRCA1 carriers with only common HRAS1 alleles. There are no conclusive studies of HRAS1 alleles in sporadic epithelial ovarian cancer. A case-control study of HRAS1 alleles was performed on DNA from 136 Caucasian patients with ovarian cancer and 108 cancer-free controls using conventional (Southern blot) and PCR-based methods to determine the frequency of rare HRAS1 alleles. Odds ratios (ORs) were estimated using unconditional logistic regression methods. A single degree of freedom test was used to assess the significance of linear trend across categories of increasing exposure. A statistically significant association between rare HRAS1 alleles and risk of ovarian cancer was observed [OR, 1.70; 95% confidence interval (CI), 1.03-2.80; P = 0.04]. Having only one rare allele was associated with a relative risk of 1.66 (95% CI, 0.91-3.01), whereas having two rare alleles increased the relative risk to 2.86 (95% CI, 0.75-10.94; trend P = 0.03). Analysis of HRAS1 allele types by the age of the case at diagnosis revealed that younger cases (<45 years) had a borderline statistically significant increased association with rare HRAS1 alleles compared to older cases (> or = 0 years; OR, 1.89; 95% CI, 0.90-3.98; P = 0.09). Rare HRAS1 alleles contribute to ovarian cancer predisposition in the general population. Thus, the HRAS1-variable number of tandem repeats locus may function as a modifier of ovarian cancer risk in both sporadic and hereditary ovarian cancer.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  T. Krontiris,et al.  Distinct mutation patterns of breast cancer-associated alleles of the HRAS1 minisatellite locus. , 1999, Human molecular genetics.

[3]  T. Petes,et al.  A mutation of the yeast gene encoding PCNA destabilizes both microsatellite and minisatellite DNA sequences. , 1999, Genetics.

[4]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[5]  M. Stratton,et al.  Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus , 1996, Nature Genetics.

[6]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[7]  J. Todd,et al.  Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus , 1995, Nature Genetics.

[8]  H. Safaii,et al.  Molecular genetic changes associated with ovarian cancer. , 1994, Gynecologic oncology.

[9]  N. Risch,et al.  An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. , 1993, The New England journal of medicine.

[10]  M. Green,et al.  Allelic variation of reporter gene activation by the HRAS1 minisatellite. , 1993, Genomics.

[11]  J. Weitzel,et al.  The HRAS1 gene cluster: two upstream regions recognizing transcripts and a third encoding a gene with a leucine zipper domain. , 1992, Genomics.

[12]  A. Berchuck,et al.  Ha-ras polymorphisms in epithelial ovarian cancer. , 1992, Gynecologic oncology.

[13]  W. Trepicchio,et al.  Members of the rel/NF-kappa B family of transcriptional regulatory proteins bind the HRAS1 minisatellite DNA sequence. , 1992, Nucleic acids research.

[14]  T. Krontiris,et al.  Minisatellite allele diversification: the origin of rare alleles at the HRAS1 locus. , 1990, American journal of human genetics.

[15]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[16]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[17]  A. Whittemore,et al.  An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[18]  P. Vineis,et al.  Racial variation in the distribution of Ha‐ras‐1 alleles , 1991, Molecular carcinogenesis.

[19]  D. Parkinson,et al.  Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients , 1985, Nature.

[20]  N. Breslow,et al.  The analysis of case-control studies , 1980 .